ClinicalTrials.gg
CompletedNCT01680328Updated Mar 3, 2017Results posted

Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations

A Phase 1 interventional study of 19 injections and sodium chloride 0.9% solution in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2017-03-03.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.

Enrollment
258th of 494
82 · median 87
Started
2012
with 36 others
Phase 1
206 of 642
1 open now
Registered
443rd of 642
by date

Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 258th largest by enrollment of the 494 interventional ones that give a count, is one of 37 that started in 2012, is one of 206 in phase 1, and was the 443rd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 642 studies in Diabetes Mellitus by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to assess and describe the pain in relation to subcutaneous (under the skin) injection of different combinations of injection speed and volume with respect to acceptance of the injection pain and backflow.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Delivery Systems
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities.
  • Type 1 or type 2 diabetes
  • Daily injection(s) with anti-diabetic drug (insulin or Glucagon like Peptide-1 (GLP-1) analogues) via pen-injector or vial/syringe for more than 6 months
  • (BMI) between 18.5 and 30.0 kg/m\^2 (both included)
  • Caucasians

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to needle, ink ball pen or other that are in contact with the injection area during the clinical visit
  • Previous participation in this trial. Participation is defined as: screened
  • Receipt of any medicinal product that can influence pain perception within 14 days before screening
  • Injection of more than 40 units of insulin per injection
  • Continuous Subcutaneous Insulin Infusion use within the last 6 months
  • Continuous Glucose Monitoring use within the last 6 months
  • Intake of any pain-relieving or analgesic within the last week (excluding low dose aspirin in cardio vascular prophylactic doses)
  • Known active or in-active skin disease in the injection area or that may affect pain perception
  • Anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular prophylactic doses is allowed. However, not on the day of the injections)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Other
    Different injection speed and volume combinations

    The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.

    Other: 19 injections · Drug: sodium chloride 0.9% solution

Interventions

  • Other19 injections

    Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).

  • Solution for injection.

06

What researchers measure

Primary outcomes

  1. Injection Pain (VAS mm)

    Calculated as the least square mean estimate of the difference in injection pain on a VAS (mm) between different factor levels corresponding to injection region, injection volume and injection speed (pain was assessed using an electronic VAS consisting of a 100 mm line where 0 mm corresponded to no pain and 100 mm corresponded to worst pain. After each injection, the subjects rated their pain perception at the electronic VAS by marking the 100 mm line).

    Time frame: 1 minute (±30 sec) after each injection

Secondary outcomes

  1. Acceptance of Injection Pain After Injection of Different Volumes.

    Acceptance of pain was rated subjectively as yes or no by the subject after each injection.

    Time frame: 1 minute (±30 seconds) after each injection

  2. Acceptance of Injection Pain After Injection at Different Speeds.

    Acceptance of pain was rated subjectively as yes or no by the subject after each injection.

    Time frame: 1 minute (±30 sec) after each injection

  3. Acceptance of Injection Pain After Injection in the Thighs Versus Abdomen.

    Acceptance of pain was rated subjectively as yes or no by the subject after each injection.

    Time frame: 1 minute (±30 seconds) after each injection

  4. Estimated Mean Differences in the Volume of Backflow (uL) in the Abdomen After Different Injection Volumes and Speeds as Compared to Needle Insertion

    Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.

    Time frame: 2 minutes (±30sec) after each injection

  5. Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion

    Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.

    Time frame: 2 minutes (±30sec) after each injection

07

Results

Posted Jun 19, 2014

Participant flow

The trial was conducted at a single site in Germany at a single visit.

Participant flow — Overall Study
MilestoneAll Participants
Started82
Subjects missing injections2
Completed80
Not completed2

Outcome measures

PrimaryInjection Pain (VAS mm)

Calculated as the least square mean estimate of the difference in injection pain on a VAS (mm) between different factor levels corresponding to injection region, injection volume and injection speed (pain was assessed using an electronic VAS consisting of a 100 mm line where 0 mm corresponded to no pain and 100 mm corresponded to worst pain. After each injection, the subjects rated their pain perception at the electronic VAS by marking the 100 mm line).

Time frame:
1 minute (±30 sec) after each injection
Reported as:
Mean · mm
Injection Pain (VAS mm)
mmThighs: Injection Region-5 s.c Injections+1 Needle InsertionAbdomen: Injection Region-12 s.c Injections+1 Needle InsertionInjection Volume 1600 μLInjection Volume 1200 μLInjection Volume 800 μLInjection Volume 400 μLInjection Speed at 450 μL/sInjection Speed at 300 μL/sInjection Speed at 150 μL/s
Needle insertion20.0 ± 24.212.8 ± 16.3NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Injection speed at 150 μL/s; AbdomenNA ± NANA ± NA20.9 ± 24.415.7 ± 20.211.6 ± 15.714.5 ± 17.3NA ± NANA ± NANA ± NA
Injection speed at 300 μL/s; AbdomenNA ± NANA ± NA17.2 ± 22.520.1 ± 25.313.7 ± 17.114.8 ± 18.1NA ± NANA ± NANA ± NA
Injection speed at 450 μL/s; AbdomenNA ± NANA ± NA21.1 ± 24.814.9 ± 16.914.8 ± 18.912.4 ± 15.5NA ± NANA ± NANA ± NA
Injection volume of 400 μL; ThighsNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA20.9 ± 24.8NA ± NA22.9 ± 25.9
Injection volume of 800 μL; ThighsNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA23.2 ± 24.5NA ± NA
Injection volume of 1600 μL; ThighsNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA31.1 ± 28.5NA ± NA31.5 ± 28.0
Statistical analysis
  • Injection Volume 800 μL vs Injection Volume 400 μL · Least squares mean: -0.1 · 95% CI -2.9 to 2.8
  • Injection Volume 1200 μL vs Injection Volume 400 μL · Least squares mean: 3.5 · 95% CI 0.4 to 6.6
  • Injection Volume 1600 μL vs Injection Volume 400 μL · Least squares mean: 7.2 · 95% CI 4.6 to 9.7
  • Injection Volume 1200 μL vs Injection Volume 800 μL · Least squares mean: 3.6 · 95% CI 0.4 to 6.7
  • Injection Volume 1600 μL vs Injection Volume 800 μL · Least squares mean: 7.2 · 95% CI 4.4 to 10.0
  • Injection Volume 1600 μL vs Injection Volume 1200 μL · Least squares mean: 3.7 · 95% CI 0.6 to 6.7
  • Injection Speed at 300 μL/s vs Injection Speed at 150 μL/s · Least squares mean: 0.4 · 95% CI -2.1 to 2.9
  • Injection Speed at 450 μL/s vs Injection Speed at 150 μL/s · Least squares mean: -0.4 · 95% CI -2.7 to 1.9
  • Thighs: Injection Region-5 s.c Injections+1 Needle Insertion vs Abdomen: Injection Region-12 s.c Injections+1 Needle Insertion · Least squares mean: 9.0 · 95% CI 6.7 to 11.3
SecondaryAcceptance of Injection Pain After Injection of Different Volumes.

Acceptance of pain was rated subjectively as yes or no by the subject after each injection.

Time frame:
1 minute (±30 seconds) after each injection
Reported as:
Number · scores
Acceptance of Injection Pain After Injection of Different Volumes.
scoresInjection Volume of 1600 μLInjection Volume of 1200 μLInjection Volume of 800 μLInjection Volume of 400 μL
Yes334218303368
No75282541
Statistical analysis
  • Injection Volume of 800 μL vs Injection Volume of 400 μL · Odds ratio (OR) · Odds ratio (or): 0.8 · 95% CI 0.5 to 1.4
  • Injection Volume of 1200 μL vs Injection Volume of 400 μL · Odds ratio (or): 2.1 · 95% CI 1.2 to 3.5
  • Injection Volume of 1600 μL vs Injection Volume of 400 μL · Odds ratio (or): 2.1 · 95% CI 1.4 to 3.0
  • Injection Volume of 1200 μL vs Injection Volume of 800 μL · Odds ratio (or): 2.6 · 95% CI 1.4 to 4.8
  • Injection Volume of 1600 μL vs Injection Volume of 800 μL · Odds ratio (or): 2.6 · 95% CI 1.4 to 4.6
  • Injection Volume of 1600 μL vs Injection Volume of 1200 μL · Odds ratio (or): 1.0 · 95% CI 0.7 to 1.5
SecondaryAcceptance of Injection Pain After Injection at Different Speeds.

Acceptance of pain was rated subjectively as yes or no by the subject after each injection.

Time frame:
1 minute (±30 sec) after each injection
Reported as:
Number · scores
Acceptance of Injection Pain After Injection at Different Speeds.
scoresInjection Speed at 450 μL/sInjection Speed at 300 μL/sInjection Speed at 150 μL/s
Yes432365426
No594466
Statistical analysis
  • Injection Speed at 300 μL/s vs Injection Speed at 150 μL/s · Odds ratio (or): 1.1 · 95% CI 0.7 to 1.8
  • Injection Speed at 450 μL/s vs Injection Speed at 150 μL/s · Odds ratio (or): 0.9 · 95% CI 0.6 to 1.2
SecondaryAcceptance of Injection Pain After Injection in the Thighs Versus Abdomen.

Acceptance of pain was rated subjectively as yes or no by the subject after each injection.

Time frame:
1 minute (±30 seconds) after each injection
Reported as:
Number · scores
Acceptance of Injection Pain After Injection in the Thighs Versus Abdomen.
scoresThighsAbdomen
Yes390978
No10187
Statistical analysis
  • Thighs vs Abdomen · Odds ratio (OR) · Odds ratio (or): 3.7 · 95% CI 2.4 to 5.5
SecondaryEstimated Mean Differences in the Volume of Backflow (uL) in the Abdomen After Different Injection Volumes and Speeds as Compared to Needle Insertion

Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.

Time frame:
2 minutes (±30sec) after each injection
Reported as:
Mean · mcL
Estimated Mean Differences in the Volume of Backflow (uL) in the Abdomen After Different Injection Volumes and Speeds as Compared to Needle Insertion
mcLAbdomen: Injection Region-12 s.c Injections+1 Needle InsertionInjection Volume 1600 μLInjection Volume 1200 μLInjection Volume 800 μLInjection Volume 400 μLInjection Speed at 450 μL/sInjection Speed at 300 μL/sInjection Speed at 150 μL/s
Needle insertion0.0 ± 0.1NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Injection speed at 150 μL/sNA ± NA2.3 ± 5.10.9 ± 1.90.5 ± 1.40.6 ± 1.8NA ± NANA ± NANA ± NA
Injection speed at 300 μL/sNA ± NA1.4 ± 2.90.8 ± 1.90.5 ± 1.60.4 ± 1.3NA ± NANA ± NANA ± NA
Injection speed at 450 μL/sNA ± NA0.6 ± 1.11.1 ± 4.60.5 ± 1.30.9 ± 2.7NA ± NANA ± NANA ± NA
Statistical analysis
  • Injection Volume 400 μL vs Injection Speed at 150 μL/s · Least square mean difference: 0.6 · 95% CI -0.6 to 1.8
  • Injection Volume 400 μL vs Injection Speed at 300 μL/s · Least square mean difference: 0.4 · 95% CI -0.8 to 1.6
  • Injection Volume 400 μL vs Injection Speed at 450 μL/s · Least square mean difference: 0.9 · 95% CI -0.4 to 2.1
  • Injection Volume 800 μL vs Injection Speed at 150 μL/s · Least square mean difference: 0.5 · 95% CI -0.8 to 1.7
  • Injection Volume 800 μL vs Injection Speed at 300 μL/s · Least square mean difference: 0.5 · 95% CI -0.8 to 1.7
  • Injection Volume 800 μL vs Injection Speed at 450 μL/s · Least square mean difference: 0.5 · 95% CI -0.7 to 1.8
  • Injection Volume 1200 μL vs Injection Speed at 150 μL/s · Least square mean difference: 0.9 · 95% CI -0.3 to 2.1
  • Injection Volume 1200 μL vs Injection Speed at 300 μL/s · Least square mean difference: 0.8 · 95% CI -0.4 to 2.0
  • Injection Volume 1200 μL vs Injection Speed at 450 μL/s · Least square mean difference: 1.1 · 95% CI -0.1 to 2.3
  • Injection Volume 1600 μL vs Injection Speed at 150 μL/s · Least square mean difference: 2.3 · 95% CI 1.0 to 3.5
  • Injection Volume 1600 μL vs Injection Speed at 300 μL/s · Least square mean difference: 1.4 · 95% CI 0.2 to 2.6
  • Injection Volume 1600 μL vs Injection Speed at 450 μL/s · Least square mean difference: 0.6 · 95% CI -0.6 to 1.8
SecondaryEstimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion

Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.

Time frame:
2 minutes (±30sec) after each injection
Reported as:
Mean · mcL
Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion
mcLThighs: Injection Region-5 s.c Injections+1 Needle InsertionInjection Volume 1600 μLInjection Volume 800 μLInjection Volume 400 μLInjection Speed at 450 μL/sInjection Speed at 300 μL/sInjection Speed at 150 μL/s
Needle insertion0.8 ± 5.6NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Injection speed at 150 μL/sNA ± NA5.6 ± 8.6NA ± NA1.0 ± 3.1NA ± NANA ± NANA ± NA
Injection speed at 300 μL/sNA ± NANA ± NA2.3 ± 7.9NA ± NANA ± NANA ± NANA ± NA
Injection speed at 450 μL/sNA ± NA2.5 ± 4.6NA ± NA1.6 ± 4.9NA ± NANA ± NANA ± NA
Statistical analysis
  • Injection Volume 400 μL vs Injection Speed at 150 μL/s · Least square mean difference: 0.3 · 95% CI -0.9 to 1.5
  • Injection Volume 400 μL vs Injection Speed at 450 μL/s · Least square mean difference: 0.8 · 95% CI -0.4 to 2.1
  • Injection Volume 800 μL vs Injection Speed at 300 μL/s · Least square mean difference: 1.6 · 95% CI 0.3 to 2.8
  • Injection Volume 1600 μL vs Injection Speed at 150 μL/s · Least square mean difference: 4.9 · 95% CI 3.7 to 6.1
  • Injection Volume 1600 μL vs Injection Speed at 450 μL/s · Least square mean difference: 1.7 · 95% CI 0.5 to 2.9

Adverse events

Collected over From Day 0 when receiving 19 injections and up to 48 hours after last injection.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—0/82 (0%)0/82 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean54.3 ± 11.9
Gender
Gender(Participants)All Participants
Female32
Male50
08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Neuss, 41460, Germany
09

References and documents

Publications

  • Heise T, Nosek L, Dellweg S, Zijlstra E, Praestmark KA, Kildegaard J, Nielsen G, Sparre T. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014 Oct;16(10):971-6. doi: 10.1111/dom.12304. Epub 2014 May 11. PubMed 24720741 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2012
First posted
Sep 7, 2012
Start
Aug 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Jun 19, 2014
Last update
Mar 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01680328
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 7, 2012
Start date
Aug 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Jun 19, 2014
Last update
Mar 3, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Chloride

Start the discussion